ArticleAbdominal imaging2015
Does focal incidental 18F-FDG PET/CT uptake in the prostate have significance?
Article in Abdominal imaging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Prostatic incidental uptake on PET/CT: an updated systematic review and meta-analysis of prevalence and malignancy risk.Frontiers in oncology · 2026Pooled it
- Multitracer comparison of gold standard PSMA-PET/CT withEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Is there a comparable Mp-MRI for incidental prostate uptake on 18 F-FDG PET/CT?World journal of surgical oncology · 2024Article
- Focal incidental colorectal fluorodeoxyglucose uptake: Should it be spotlighted?World journal of clinical cases · 2024Article
- Unexpected focal fluorodeoxyglucose uptake in main organs; pass through or pass by?World journal of clinical cases · 2024Review
- The risk of prostate cancer on incidental finding of an avid prostate uptake on 2-deoxy-2-[Asian journal of urology · 2024Article
- Significance of incidental focal fluorine-18 fluorodeoxyglucose uptake in colon/rectum, thyroid, and prostate: With a brief literature review.World journal of clinical cases · 2022Article
- A decade of multi-modality PET and MR imaging in abdominal oncology.The British journal of radiology · 2021Review
- Prevalence of focal incidental breast uptake on FDG-PET/CT and risk of malignancy: a systematic review and meta-analysis.European journal of hybrid imaging · 2019Review
- Novel Imaging in Detection of Metastatic Prostate Cancer.Current oncology reports · 2019Review
- Clinical significance of prostateWorld journal of radiology · 2017Article
- Advances in Imaging in Prostate and Bladder Cancer.Current urology reports · 2017Review
- Is There Use for FDG-PET in Prostate Cancer?Seminars in nuclear medicine · 2016Review
- PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Review
- Update on advances in molecular PET in urological oncology.Japanese journal of radiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
purpose(18)F-FDG PET/CT is used to characterize many malignancies, but is not recommended for localized prostate cancer. This study explores the value of multi-parametric MRI (mpMRI) in characterizing incidental prostate (18)F-FDG uptake.
methodsThirty-one patients who underwent (18)F-FDG PET/CT for reasons unrelated to prostate cancer and prostate mpMRI were eligible for this retrospective study. The mpMRI included T2-weighted (T2W), dynamic contrast enhancement (DCE), apparent diffusion coefficient (ADC), and MR spectroscopy (MRS) sequences. Fourteen patients were excluded (n = 8 insufficient histopathology, n = 6 radical prostatectomy before PET), and final analysis included 17 patients. A nuclear medicine physician, blinded to clinicopathologic findings, identified suspicious areas and maximum standardized uptake values (SUV max) on (18)F-FDG PET/CT. Sector-based imaging findings were correlated with annotated histopathology from whole-mount or MRI/transrectal ultrasound fusion biopsy samples. Positive predictive values (PPVs) were estimated using generalized estimating equations with logit link. Results were evaluated with Kruskal-Wallis and Dunn's multiple comparisons tests.
resultsThe PPV of (18)F-FDG PET alone in detecting prostate cancer was 0.65. Combining (18)F-FDG PET as a base parameter with mpMRI (T2W, DCE, ADC, and MRS) increased the PPV to 0.82, 0.83, 0.83, and 0.94, respectively. All benign lesions had SUV max < 6. Malignant lesions had higher SUV max values that correlated with Gleason scores. There was a significant difference in SUV max per prostate between the Gleason ≥ 4 + 5 and benign categories (p = 0.03).
conclusionsFocal incidental prostate (18)F-FDG uptake has low clinical utility alone, but regions of uptake may harbor high-grade prostate cancer, especially if SUV max > 6. Using mpMRI to further evaluate incidental (18)F-FDG uptake aids the diagnosis of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.